The management of chronic myeloid leukemia remains a significant challenge despite the introduction of effective tyrosine kinase inhibitors. At the 20th Congress of the European Hematology Association (EHA), Stephen O’Brien, BSc (Hons), PhD, MBChB, FRCP, FRCPath, of the University of Newcastle, Newcastle upon Tyne, UK, explains possible new strategies that may improve the outlook for these patients.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates